VolitionRx Limited (VNRX) Starts Presentation at Marcum MicroCap Conference

VolitionRx Limited (NYSE: VNRX) is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present. VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S., and ultimately, worldwide. For more information, visit the company’s website at www.volitionrx.com